Guillermo Garcia-Manero, MD, and Hagop Kantarjian, MD, discuss the phase 3 VERONA trial at SOHO 2025. Visit the SOHO 2025 meeting news page for more coverage from the meeting.  

Thomas G. Martin, MD, of the University of California, San Francisco, and Robert Orlowski, MD, PhD, of the University of Texas MD Anderson Cancer Center, take part in today’s myeloma debate centered around frontline and maintenance treatment. Don’t miss this engaging session.

Today, Jennifer R. Brown, MD, PhD, will be honored with the Michael J. Keating Outstanding Achievement Award, which recognizes a clinician’s significant research contributions to advancing hematologic oncology treatment.

We have very good speakers and some really interesting topics at this year’s CLL session. The session opens with Dr. Lydia Scarfò’s presentation on next-generation sequencing (NGS) and what to do when additional abnormalities are found at diagnosis.

A study presented by Meletios Dimopoulos, MD, of the National and Kapodistrian University of Athens, as part of the SOHO 2025 Annual Meeting, showed that daratumumab monotherapy in patients with high-risk smoldering multiple myeloma (SMM) demonstrated “an opportunity to delay or even prevent end-organ damage and progression to MM while maintaining quality of life and improving survival.”

The Society of Hematologic Oncology (SOHO) announced the abstract award winners of its 13th Annual Meeting at Wednesday evening’s award ceremony, presenting eight awards, including five honorable mentions.

The myeloproliferative neoplasms (MPNs) session this morning will bring together a full spectrum of timely topics, from novel therapies in polycythemia vera (PV) and essential thrombocythemia (ET) to new questions about transplantation, according to Gabriela Hobbs, MD, of Massachusetts General Hospital and the SOHO 2025 MPN session co-chair.

A phase 1/2 study showed that iberdomide, daratumumab, and dexamethasone (IBERDd) had a manageable safety profile when used in transplant-ineligible, newly diagnosed multiple myeloma (MM).

One of SOHO’s most dedicated and longest-standing members, Dr. Lonial chairs the Education Committee, serves as Treasurer, and is editor in chief of the society’s news publication, SOHO Insider. Today, he will receive the Emil J. Freireich Distinguished Pioneer Award.

These are truly transformative times in the field of hematologic malignancies. Diseases that were once considered untreatable are now being managed—and in some cases cured—thanks to cutting-edge therapies. Just a few years ago, such outcomes would have seemed unimaginable. However, as we travel the world, we are constantly reminded of the urgent need to make these advancements accessible on a global scale.